

<input type="checkbox"/> New to Therapy
<input type="checkbox"/> Current Therapy

Patient Information

Patient Name: _____
 Date of Birth: _____ Sex: _____ SS# _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Home Phone: _____ Work Phone: _____
 Cell Phone: _____ E-mail: _____
 Please attach copy of front and back of patient's prescription ins. card(s) if applicable
 Insurance Company Name: _____
 Insurance Company Phone: _____
 Policy holder: _____
 Policy holder Employer: _____
 Relationship to Patient: _____
 ID# _____ Group# _____
 RxBIN: _____ RxPCN: _____

Prescriber Information

Practice/ Organization Name: _____
 Physician Name: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone#: _____ Fax#: _____
 DEA# _____ NPI# _____
 License#: _____ Medicaid UPIN#: _____
 Physician Specialty: _____
Date Shipment Needed: _____
Ship to: Patient Prescriber Other
 Shipment Address: _____ Attn: _____
 City: _____ State: _____ Zip: _____

If shipped to the physician's office, physician accepts on behalf of patient for administration in office.

Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.

Clinical Information and Prescription

Diagnosis: L40. __ Psoriasis L40.54 Juvenile Psoriatic Arthritis L40.59 Psoriatic Arthritis Other: _____
 Date of Diagnosis or Years with Disease: _____ Allergies (NKDA): _____
 Patient Weight: _____ Patient Height: _____ NEGATIVE tuberculin skin test? YES NO
 BSA (Body Surface Area) affected by Psoriasis: _____% Has Hepatitis B been ruled out? YES NO
 Prior Failed Medications and Date _____
 Expected First Dose Date: _____ Injection Instruction needed: YES NO In-office administration or training

- Cimzia**® (certolizumab pegol) Prefilled Syringes OR Vials Inject 400 mg SC every other week
 - Initial: Inject 400 mg SC initially and at weeks 0, 2 and 4, followed by 200 mg every other week (Wt ≤90 kg)
 - Maintenance: Inject 200 mg SC every other week (Wt ≤90 kg)
- Cosentyx**® (secukinumab) Pen Auto injector OR Prefilled Syringe 150 mg OR 300 mg
 - Initial: Inject SC at weeks 0,1,2,3,4, then SC every 4 weeks Maintenance: Inject SC every 4 weeks
- Enbrel**® (etanercept) 50mg SureClick 50mg Mini AutoTouch 50mg PF Syringe 25mg PF Syringe 25mg Vial
 - Initial: Inject 50 mg SC twice per week (3-4 days apart) x 3 months
 - Maintenance: Inject 50mg SC once per week Other: _____
- Humira**® (adalimumab) 40mg Prefilled Syringe OR 40mg Pen Auto injector Requesting citrate/buffer free
 - Initial: Inject 80 mg SC Day 1, then 40mg Day 8, then 40mg every other week thereafter
 - Maintenance: Inject 40mg SC every two weeks Other: _____
- Ilumya**® (Tildrakizumab) 100mg/ml Prefilled Syringe
 - Initial: Inject SC at weeks 0, 4 and then every 12 weeks thereafter Maintenance: Inject SC every 12 weeks
- Otezla**® (apremilast) Initial: Take as directed per starter pack Maintenance: Take 30mg by mouth twice daily
- Remicade**® (infliximab) OR **Inflectra**® (infliximab-dyyb) OR **Renflexis**® (infliximab-abda)
 - Initial: Infuse 5mg/kg IV infusion at weeks 0,2,6, then 5mg/kg IV infusion every 8 weeks
 - Maintenance: Infuse 5mg/kg IV infusion every 8 weeks *Must provide patient's weight
- Siliq**® (brodalumab) 210 mg/1.5ml Prefilled Syringe
 - Initial: Inject SC at weeks 0,1, and 2 then every 2 weeks thereafter Maintenance: Inject SC every 2 weeks
- Skyrizi**® (Risankizumab) 75 mg/0.83 mL Prefilled Syringe Initial: Inject 150 mg SC at weeks 0, 4 and then every 12 weeks thereafter Maintenance: Inject 150 mg SC every 12 weeks thereafter
- Stelara**® (ustekinumab) 45mg Prefilled Syringe (wt<100kg) 90mg Prefilled Syringe (wt >100kg)
 - Initial: Inject SC at weeks 0,4, then every 12 weeks thereafter Maintenance: Inject SC every 12 weeks
- Taltz**® (ixekizumab) 80mg/ml Prefilled Syringe OR 80mg/ml Auto injector
 - Initial: Inject 160 mg SC at week 0, 80 mg SC at weeks 2,4,6,8,10,12 followed by 80mg SC every 4 weeks
 - Maintenance: Inject 80 mg SC every 4 weeks
- Tremfya**® (guselkumab) 100mg/ml Prefilled Syringe One-Press Patient-Controlled Injector
 - Initial: Inject SC at weeks 0, 4 and then every 8 weeks thereafter Maintenance: Inject SC every 8 weeks

Quantity Prescribed: QS 30 days Other: _____ **Refills Authorized:** 0 1 2 3 6 mos 1 yr _____

X _____ / ____ / ____
Physician Signature (no stamps) **Date**